로딩 중…
지수 로딩 중…
Samyang Biopharm Corporation
0120G0· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩47,600-4.80%
2026-06-19
Price Chart
Samyang Biopharm Corporation
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 353.95B KRW |
| Revenue | 28.59B KRW |
| Net Income | 2.24B KRW |
| Total Assets | 339.28B KRW |
| Net Assets | 234.73B KRW |
| Value | |
| P/E | 158.26x |
| P/B | 1.51x |
| P/S | 12.38x |
| EV/EBITDA | 149.41x |
| FCF Yield | 0.86% |
| Profitability | |
| ROE | 0.95% |
| ROA | 0.66% |
| Op. Margin | 9.41% |
| Financial Health | |
| Debt Ratio | 44.54% |
| Total Debt | 77.82B KRW |
| FCF | 3.05B KRW |
| Cash | 29.68B KRW |
| Current Ratio | 1.68x |
| Net Debt/EBITDA | 17.89x |
| Performance | |
| 1M Return | -19.46% |
| From 52W High | -68.46% |
| 1Y MDD | -66.78% |
| Trading | |
| Volume | 38,975 shares |
| Foreign Own. | 4.43% |
| Per Share | |
| EPS | 1,861 KRW |
| BPS | 31,937 KRW |
Company Info
Samyang Biopharm is a company operating in the pharmaceutical bio business, newly established through a spin-off from Samyang Holdings. It develops new drugs and improved new drugs based on innovative technologies, including drug delivery platforms (DDS), polymer nanoparticle technology, and siRNA/mRNA-based delivery technology. The company holds the top position in the domestic cytotoxic anticancer drug market (with Genexol, Pemed) and the global biodegradable suture thread market, demonstrating high technological capabilities and market share. Samyang Biopharm was established in 2025 and is headquartered in Seongnam-si, Gyeonggi-do.